Therapeutic Use of Hyaluronan-Based Products

Carbohydrate Chemistry, Biology and Medical Applications

Volumn , Issue , 2008, Pages 311-332

  Balazs, Endre A ^a   Band, Philip A ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84883987955     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-08-054816-6.00014-8     Document Type: Chapter

References (108)

1. EA Balazs, MI Freeman, R Klöti, G Meyer-Schwickerath, F Regnault and DB Sweeney (1971) The utilization of hyaluronic acid for intravitreal injection. MP Solanes (Eds) ACTA XXI Concilium Ophthalmologicum Mexico, Part I Amsterdam: Excerpta Medica 555-558.
2. EA Balazs, MI Freeman, R Klöti, G Meyer-Schwickerath, F Regnault and DB Sweeney (1972) Hyaluronic acid and the replacement of vitreous and aqueous humor. EB Streiff (Eds) Modern Problems in Ophthalmology (Secondary Detachment of the Retina, Lausanne, 1970) Basel: S. Karger 3-21.
3. R Klöti (1972) Hyaluronsäure als Glaskörpersubstituent. Schweiz Ophthal Ges 165 351-359.
4. F Regnault (1971) Acide hyaluronique intravitéen et cryocoagulatin dans le traitement des formes graves de décollement de la rétine. Bull Soc Ophthalmol Fr 84 106-112.
5. G Meyer-Schwickerath (1974) Further experience with Healon® (hyaluronic acid) in retinal detachment surgery. Mod Probl Ophthal 12 384.
6. P Algvere (1971) Intravitreal implantation of a high-molecular hyaluronic acid in surgery for retinal detachment. Acta Ophthalmol 49 975-976.
7. J Edmund (1976) Comments on the clinical use of Healon and a short survey of the use of intraocular injection of hyaluronic acid. AR Irvine, C O'Malley (Eds) Advances in Vitreous Surgery Springfield, IL: C. Thomas 624-625.
8. N Rydell and EA Balazs (1971) Effect of intra-articular injection of hyaluronic acid on the clinical symptoms of osteoarthritis and on granulation tissue formation. Clin Orthop 80 25-32.
9. Balazs EA. Ultrapure hyaluronic acid and the use thereof. US Patent 4,141,973 (1979)
10. EA Balazs, D Miller and R Stegmann (1979) Viscosurgery and the use of Na-hyaluronate in intraocular lens implantation. International Congress and First Film Festival on Intraocular Implantation, Cannes, France 1-6.
11. EL Graue, FM Polack and EA Balazs (1980) The protective effect of Na-hyaluronate to corneal endothelium. Exp Eye Res 31 119-127.
12. LG Pape and EA Balazs (1980) The use of sodium hyaluronate (Healon®) in human anterior segment surgery. Ophthalmol 87 699-705.
13. D Miller (1980) Use of Na-hyaluronate in anterior segment eye surgery. Am Intraocular Implant Soc J 6 13-15.
14. G Meyer-Schwickerath (Eds) (1982) Viskochirurgie des Auges: Beiträge des ersten nationalen Healon®-Symposiums October 15 & 16
15. D Miller and R Stegmann (Eds) (1983) Healon (Sodium Hyaluronate): A Guide to Its Use in Ophthalmic Surgery New York, NY: John Wiley & Sons
16. G Eisner (Eds) (1986) Ophthalmic Viscosurgery: A Review of Standards, Techniques and Applications Montreal, Canada: Medicopea
17. SA Arshinoff (1999) Dispersive-cohesive viscoelastic soft shell technique. J Cataract Refract Surg 25 167-173.
18. S Arshinoff (2004) Ultimate soft-shell technique and AcrySof Monarch injector cartridges. J Cataract Refract Surg 30 1809-1810.
19. JJ Alpar (1986) Sodium hyaluronate (Healon) in glaucoma filtering procedures. Ophthalmic Surg 17 724-730.
20. RG Carassa, P Bettin, M Fiori and R Brancato (2003) Viscocanalostomy versus trabeculectomy in white adults affected by open-angle glaucoma: a 2-year randomized, controlled trial. Ophthalmology 110 882-887.
21. L Buratto, P Giardini and R Bellucci (Eds) (2000) Viscoelastics in Ophthalmic Surgery Thorofare, NJ: Slack, Inc.
22. EA Balazs and JL Denlinger (1993) Viscosupplementation: a new concept in the treatment of osteoarthritis. J Rheumatol 20(Suppl 39), 3-9.
23. EA Balazs (2004) Viscosupplementation for treatment of osteoarthritis: from initial discovery to current status and results. Surg Technol Int 12 278-289.
24. American College of Rheumatology Subcommittee on Osteoarthritis (2000) Recommendations for the medical management of osteoarthritis of the hip and knee. Arthr Rheum 43 1905-1915.
25. KM Jordan, NK Arden, M Doherty, B Bannwarth, JW Bijlsma, P Dieppe, K Günther, H Hauselmann, G Herrero-Beaumont, P Kaklamanis, S Lohmander, B Leeb, M Lequesne, B Mazieres, E Martin-Mola, K Pavelka, A Pendleton, L Punzi, U Serni, B Swoboda, G Verbruggen, I Zimmerman-Gorska and M Dougados (2003) EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis. Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 62 1145-1155.
26. N Bellamy, J Campbell, V Robinson, T Gee, R Bourne and G Wells (2005) Viscosupplementation for the treatment of osteoarthritis of the knee (Cochrane Review) (comparing hyaluronan and hylan derivatives). Cochrane Database Syst Rev 1-429. Art. No. CD005321. DOI:10.1002/14651858.CD005321
27. CT Wang, J Lin, CJ Chang, YT Lin and SM Hou (2004) Therapeutic effects of hyaluronic acid on osteoarthritis of the knee: A meta-analysis of randomized controlled trials. J Bone Joint Surg Am 86-A 538-545.
28. GH Lo, M LaValley, T McAlindon and DT Felson (2003) Intra-articular hyaluronic acid in treatment of knee osteoarthritis: a meta-analysis. JAMA 290 3115-3121.
29. A Kahan, PL Lieu and L Salin (2003) Prospective randomized study comparing the medicoeconomic benefits of Hylan GF-20 vs. conventional treatment in knee osteoarthritis. Joint Bone Spine 70 276-281.
30. J.P. Raynauld J-P, GW Torrance, PA Band, CH Goldsmith, P Tugwell, V Walker, M Schultz and N Bellamy (2002) A prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation of hylan GF-20 into the treatment paradigm for patients with knee osteoarthritis (Part 1 of 2): clinical results. Osteoarth Cartilage 10 506-517.
31. GW Torrance, JP Raynauld, V Walker, CH Goldsmith, N Bellamy, PA Band, M Schultz and P Tugwell (2002) A prospective, randomized, health outcomes trial evaluating the incorporation of hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis (Part 2 of 2): economic results. Osteoarth Cartilage 10 518-527.
32. Intra-articular injections for osteoarthritis of the knee. Med Lett Drugs Ther 48 25-27.
33. Special report: intra-articular hyaluronan for osteoarthritis of the knee. Technol Eval Cent Asess Program Exec Summ 19 1-2.
34. Intra-articular hyaluronan injections for treatment of osteoarthritis of the knee. Tecnologica MAP Suppl 6-10.
35. United States Food and Drug Administration (1997) Center for Devices and Radiological Health. New Device Approval Letter: Synvisc®—PMA P940015. Summary of Safety and Effectiveness Data www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMA/pma.cfm?ID=5689 August 8
36. United States Food and Drug Administration (2001) Center for Devices and Radiological Health. New Device Approval Letter: Supartz™—PMA P980044. Summary of Safety and Effectiveness Data www.fda.gov/cdrh/pdf/P010029.html January 24
37. United States Food and Drug Administration. Center of Devices and Radiological Health (2004) New Device Approval Letter: Nuflexxa—PMA P010029. Summary of Safety and Effectiveness Data www.fda.gov/cdrh/pdf/P010029.html December 3
38. United States Food and Drug Administration Center for Devices and Radiological Health (2004) New Device Approval Letter: Orthovisc® High Molecular Weight Hyaluronan—PMA P030019. Summary of Safety and Effectiveness Data www.fda.gov/cdrh/pdf3/p030019.html February 4
39. United States Food and Drug Administration. Center for Devices and Radiological Health (1997) New Device Approval. Hyalgan®—PMA P950027 www.fda.gov.cdrh/pdf/P950027.pdf May 28
40. Y Ohshima, S Yokota, K Kasama and H Ono (2004) Comparative studies on levels of proteins, bacterial endotoxins and nucleic acids in hyaluronan preparations used to treat osteoarthritis of the knee—could residual proteins and bacterial endotoxins relate to complications. Jpn Pharmacol Ther 32 655-662.
41. MN Wolfe, DR Lichtenstein and G Singh (1999) Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. N Eng J Med 340 1888-1899.
42. RD Altman, R Moskowitz, S Jacobs, M Daley, J Udell and R Levin (2005) A double-blind, randomized trial of intra-articular sodium hyaluronate for the treatment of chronic shoulder pain. 69th Annual Meeting of the American College of Rheumatology, November 12–17, 2005, San Diego, CA
43. T Conrozier and E Vignon (2005) Is there evidence to support the inclusion of viscosupplementation in the treatment paradigm for patients with hip osteoarthritis. Clin Exp Rheumatol 23 711-716.
44. T Conrozier, P Bertin, P Mathieu, J Charlot, F Bailleul, R Treves, E Vignon and X Chevalier (2003) Intra-articular injections of hylan G-F 20 in patients with symptomatic hip osteoarthritis: an open-label, multicentre, pilot study. Clin Exp Rheumatol 21 605-610.
45. AGH Witteveen, S Giannini, G Guido, J Jerosch, H Lohrer and CN van Dijk (2006) Prospective study of the safety and efficacy of hylan G-F 20 (Synvisc®) in patients with symptomatic ankle osteoarthritis. American College of Rheumatology 70th Annual Meeting, Washington, D.C., November 10–15
46. X Chevalier, J Jerosch, FP Luyten, CN van Dijk, P Goupille, D Scott, F Bailleul and K Pavelka (2007) A double-blind, randomized placebo-controlled evaluation of the efficacy and safety of a single dose of 6 mL of hylan G-F 20 in patients with symptomatic osteoarthritis of the knee. EULAR Barcelona, Spain, June 13–16
47. RD Altman, C Akermark, AD Beaulieu and T Schnitzer (2004) Efficacy and safety of a single intra-articular injection of non-animal stabilized hyaluronic acid (NASHA) in patients with osteoarthritis of the knee. Osteoarthritis Cartilage 12 642-649.
48. EA Balazs and JL Denlinger (1985) Sodium hyaluronateand joint function. Equine Vet Sci 5 217-228.
49. S Gotoh, JI Onaya, M Abe, K Miyazaki, A Hamai, K Horie and K Tokuyasu (1993) Effects of the molecular weight of hyaluronic acid and its action mechanisms on experimental joint pain in rats. Ann Rheum Dis 52 817-822.
50. K Miyazaki, S Gotoh, H Ohkawara and T Yamaguchi (1984) Studies on analgesic and anti-inflammatory effects of sodium hyaluronate (SPH). Pharmacometrics 28 1123-1135.
51. S Aihara, N Murakami, R Ishii, K Kariya, Y Azuma, K Hamada, J Umemoto and S Maeda (1992) Effects of sodium hyaluronate on the nociceptive response of rats with experimentally induced arthritis. Folia Pharmacol Jpn 100 359-365.
52. MA Pozo, EA Balazs and C Belmonte (1997) Reduction of sensory responses to passive movements of inflamed knee joints by hylan, a hyaluronan derivative. Exp Brain Res 116 3-9.
53. A Gomis, M Pawlak, EA Balazs, RF Schmidt and C Belmonte (2004) Effects of different molecular weight elastoviscous hyaluornan solutions on articular nociceptive afferents. Arthr Rheum 50 314-326.
54. EA Balazs (2003) Analgesic effect of elastoviscous hyaluronan solutions and the treatment of arthritic pain. Cells, Tissues, Organs 174 49-62.
55. A Gomis, A Miralles, RF Schmidt and C Belmonte (2007) Nociceptive nerve activity in an experimental model of knee joint osteoarthritis of the guinea pig: effect of intra-articular hyaluronan application. Pain 130 126-136.
56. EA Balazs (2004) Viscoelastic properties of hyaluronan and its therapeutic use. HG Garg, CA Hales (Eds) Chemistry and Biology of Hyaluronan Amsterdam: Elsevier, Ltd. 415-455.
57. D Piacquadio, M Jarcho and R Goltz (1997) Evaluation of hylan b gel as a soft-tissue augmentation implant material. J Am Acad Dermatol 36 544-549.
58. AW Klein (2006) Soft tissue augmentation 2006: filler fantasy. Dermatol Ther 19 129-133.
59. C Lindqvist, S Tveten, BE Bondevik and D Fagrell (2005) A randomized, evaluator-blind, multicenter comparison of the efficacy and tolerability of Perlane versus Zyplast in the correction of nasolabial folds. Plast Reconstr Surg 115 282-289.
60. EA Balazs, E Leshchiner, N Larsen and P Band (1995) Hyaluronan biomaterials: medical applications. DL Wise (Eds) Handbook of Biomaterials and Applications New York: Marcel Dekker Inc. 1693-1715.
61. United States Food and Drug Administration Center for Devices and Radiological Health (2004) New Device Approval Letter: Hylaform® (hylan B gel)—PMA P030032. Summary of Safety and Effectiveness Data www.fda.gov/cdrh/pdf3/p030032.html April 22
62. United States Food and Drug Administration Center for Devices and Radiological Health (2003) New Device Approval Letter: Restylane® Injectable Gel—PMA P020023. Summary of Safety and Effectiveness Data www.fda.gov/cdrh/pdf2/P020023.html December 12
63. United States Food and Drug Administration Center for Devices and Radiological Health (2007) New Device Approval Letter: PERLANE® Injectable Gel—PMA P040024/S6. Summary of Safety and Effectiveness Data www.fda.gov/cdrh/pdf4/P040024s006.html May 2
64. United States Food and Drug Administration. Center for Devices and Radiological Health (2006) New Device Approval Letter: JUVÉDERM™—PMA P050047. Summary of Safety and Effectiveness Data www.fda.gov/cdrh/pdf5/P050047b.pdf June 2
65. United States Food and Drug Administration. Center for Devices and Radiological Health (2004) New Device Approval Letter: Hylaform® Plus (hylan B gel)—PMA P030032/S001. Summary of Safety and Effectiveness Data www.fda.gov/cdrh/pdf3/p030032s001b.pdf October 13
66. United States Food and Drug Administration (2006) Center for Devices and Radiological Health. New Device Approval Letter: Cosmetic Tissue Augmentation product (CTA)—PMA P050033. Summary of Safety and Effectiveness Data www.fda.gov/cdrh/pdf5/p050033b.pdf December 20
67. GD Monheit and KM Coleman (2006) Hyaluronic acid fillers. Dermatol Ther 19 141-150.
68. A Carruthers, W Carey, C De Lorenzi, K Remington, D Schachter and S Sapra (2005) Randomized, double-blind comparison of the efficacy of two hyaluronic acid derivatives, restylane perlane and hylaform, in the treatment of nasolabial folds. Dermatol Surg 31 1591-1598. discussion 1598
69. S Hertegård, Å Dahlqvist, C Laurent, A Borzacchiello and L Ambrosio (2003) Viscoelastic properties of rabbit vocal folds after augmentation. Otolaryngol Head Neck Surg 128 401-406.
70. L Hallén, C Johannson and C Laurent (1999) Cross-linked hyaluronan (Hylan B gel): a new injectable remedy for treatment of vocal fold insufficiency—an animal study. Acta Otolaryngol (Stockh) 119 107-111.
71. S Hertegård, L Hallen, C Laurent, E Lindstrom, K Olofsson and P Testad (2004) Cross-linked hyaluronan versus collagen for injection treatment of glottal insufficiency: 2-year follow-up. Acta Oto-Larynologica 124 1208-1214.
72. EA Balazs (1971) Hyaluronic acid and matrix implantation 2nd edn. Arlington, MA: Biotrics, Inc.
73. EA Balazs, PA Band, JL Denlinger, AI Goldman, NE Larsen, EA Leshchiner, A Leshchiner and B Morales (1991) Matrix engineering. Blood Coagul Fibrinolysis 2 173-178.
74. EA Balazs and Z Darzynkiewicz (1973) The effect of hyaluronic acid on fibroblasts, mononuclear phagocytes and lymphocytes. E Kulonen, J Pikkarainen (Eds) Biology of the Fibroblast (Papers of the Symposim held in Turku, Finland, 1972) London: Academic Press 237-252.
75. C Weiss (2002) The control of adhesions with hylan polymers. JF Kennedy, GO Phillips, PA Williams, VC Hascall (Eds) Hyaluronan Volume 2 Biomedical, Medical and Clinical Aspects Cambridge, UK: Woodhead 483-490.
76. C Weiss, HJ Levy, J Denlinger, J Suros and H Weiss (1986) The role of Na-hylan in reducing postsurgical tendon adhesions. Bull Hosp Jt Dis 46 9-15.
77. C Weiss, JM Suros, A Michalow, J Denlinger, M Moore and W Tejeiro (1987) The role of Na-hylan in reducing postsurgical tendon adhesions: Part 2. Bull Hosp Jt Dis 47 31-39.
78. R St. Onge, C Weiss, JL Denlinger and EA Balazs (1980) A preliminary assessment of Na-hyaluronate injection into “no man's land” for primary flexor tendon repair. Clin Orthop 146 269-275.
79. M Diamond (1996) Reduction of adhesions after uterine myomectomy by Seprafilm membrane (HAL-F): a blinded, prospective, randomized, multicenter clinical study. Fertil Steril 66 904-910.
80. J Becker, M Dayton, V Fazio, D Beck, S Stryker, S Wexner, B Wolff, P Roberts, L Smith, S Sweeney and M Moore (1996) Prevention of postoperative abdominal adhesions by a sodium hyaluronate-based bioresorbable membrane: a prospective, randomized, double-blind multicenter study. J Am Coll Surg 183 297-306.
81. VW Fazio, Z Cohen, JW Fleshman, H van Goor, JJ Bauer, BG Wolff, M Corman, RW Beart Jr., SD Wexner, JM Becker, JR Monson, HS Kaufman, DE Beck, HR Bailey, KA Ludwig, MJ Stamos, A Darzi, R Bleday, R Dorazio, RD Madoff, LE Smith, S Gearhart, K Lillemoe and J Gohl (2006) Reduction in adhesive small-bowel obstruction by Seprafilm adhesion barrier after intestinal resection. Dis Colon Rectum 49 1-11.
82. JL Denlinger (1976) Biotrics, Inc., Report; 1976
83. FM Polack and MT McNiece (1982) The treatment of dry eyes with Na hyaluronate (Healon®). Cornea 1 133-136.
84. MC Acosta, J Gallar and C Belmonte (1999) The influence of eye solutions on blinking and ocular comfort at rest and during work at video display terminals. Exp Eye Res 68 663-669.
85. SA Arshinoff and E Khoury (1997) HsS versus a balanced salt solution as a corneal wetting agent during routine cataract extraction and lens implantation. J Cataract Refract Surg 23 1221-1225.
86. SA Alexander and RB Donoff (1980) The glycosaminoglycans of open wounds. J Surg Res 29 422-429.
87. EA Balazs and HJ Holmgren (1949) Effect of sulfomucopolysaccharides on growth of tumor tissue. Proc Soc Exp Biol Med 72 142-145.
88. HJ Holmgren and EA Balazs (1950) Experimental studies on wound healing. Nord Med 43 471-474.
89. N Rydell, MI Freeman and EA Balazs (1969) Decreased granulation tissue reaction after instillation of hyaluronic acid Boston, MA: Retina Foundation
90. G Abatangelo, M Martelli and P Vecchia (1983) Healing of hyaluronic acid-enriched wounds: histological observations. J Surg Res 35 410-416.
91. PW Dillon, K Keefer, JH Blackburn, PE Houghton and TM Krummel (1994) The extracellular matrix of the fetal wound: hyaluronic acid controls lymphocyte adhesion. J Surg Res 57 170-173.
92. BA Mast, RF Diegelmann, TM Krummel and IK Cohen (1992) Scarless wound healing in the mammalian fetus. Surgery, Gynecol Obstetrics 174 441-451.
93. BA Mast, LC Flood, JH Haynes, RL Depalma, IK Cohen, RF Diegelmann and TM Krummel (1991) Hyaluronic acid is a major component of the matrix of fetal rabbit skin and wounds: implications for healing by regeneration. Matrix 11 63-68.
94. EA Balazs, IK Eliezer, RA Dennebaum, NE Larsen and JL Whetstone (2002) Cell attachment and growth on solid hyaluronan (hylan B gel). JF Kennedy, GO Phillips, PA Williams, VC Hascall (Eds) Hyaluronan Volume 2 Biomedical, Medical and Clinical Aspects Cambridge, UK: Woodhead 33-38.
95. K Ghosh, X.D. Ren X-D, XZ Shu, GD Prestwich and RAF Clark (2006) Fibronectin functional domains coupled to hyaluronan stimulate adult human dermal fibroblast responses critical for wound healing. Tissue Eng 12 601-613.
96. K Ghosh, Z Pan, E Guan, S Ge, Y Liu, T Nakamura, X.D. Ren X-D, M Rafailovich and RAF Clark (2007) Cell adaptation to a physiologically relevant ECM mimic with different viscoelastic properties. Biomaterials 28 671-679.
97. Y Fujimori, K Ueda, H Fumimoto, K Kubo and Y Kuroyanagi (2006) Skin regeneration for children with burn scar contracture using autologous cultured dermal substitutes and superthin auto-skin grafts: preliminary clinical study. Ann Plast Surg 57 408-414.
98. C Caravaggi, R De Giglio, C Pritelli, M Sommaria, S Dalla Noce, E Faglia, M Mantero, G Clerici, P Fratino, L Dalla Paola, G Mariani, R Mingardi and A Morabito (2003) HYAFF 11-based autologous dermal and epidermal grafts in the treatment of noninfected diabetic plantar and dorsal foot ulcers: a prospective, multicenter, controlled, randomized clinical trial. Diabetes Care 26 2853-2859.
99. A Gobbi, E Kon, M Berruto, R Francisco, G Filardo and M Marcacci (2006) Patellofemoral full-thickness chondral defects treated with hyalograft-C: a clinical, arthroscopic, and histologic review. Am J Sports Med 34 1763-1773.
100. S Nehrer, S Domayer, R Dorotka, K Schatz, U Bindreiter and R Kotz (2006) Three-year clinical outcome after chondrocyte transplantation using a hyaluronan matrix for cartilage repair. Eur J Radiol 57 3-8.
101. M Marcacci, M Berruto, D Brocchetta, A Delcogliano, D Ghinelli, A Gobbi, E Kon, L Pederzini, D Rosa, GL Sacchetti, G Stefani and S Zanasi (2005) Articular cartilage engineering with hyalograft C: 3-year clinical results. Clin Orthop Relat Res 435 96-105.
102. XZ Shu and G Prestwich (2004) Therapeutic biomaterials from chemically-modified hyaluronan. HG Garg, CA Hales (Eds) Chemistry and Biology of Hyaluronan Amsterdam: Elsevier, Ltd. 475-504.
103. GD Prestwich, XZ Shu, Y Liu, S Cai, JF Walsh, CW Hughes, S Ahmad, KR Kirker, B Yu, RR Orlandi, AH Park, SL Thibeault, S Duflo and ME Smith (2006) Injectable synthetic extracellular matrices for tissue engineering and repair. Adv Exp Med Biol 585 125-133.
104. XZ Shu, S Ahmad, Y Liu and GD Prestwich (2006) Synthesis and evaluation of injectable, in situ cross-linkable synthetic extracellular matrices for tissue engineering. J Biomed Mater Res A 79 902-912.
105. G Prestwich (2007) Synthetic extracellular matrices for 3-D cell growth: applications in reparative medicine and cell biology. Seventh (7th) International Conference on Hyaluronan (Book of Abstracts). Charleston, SC, April 22–27 8.
106. RR Orlandi, XZ Shu, L McGill, E Petersen and GD Prestwich (2007) Structural variations in a single hyaluronan derivative significantly alter wound-healing effects in the rabbit maxillary sinus. Laryngoscope 117 1288-1295.
107. M Proctor, K Proctor, XZ Shu, LD McGill, GD Prestwich and RR Orlandi (2006) Composition of hyaluronan affects wound healing in the rabbit maxillary sinus. Am J Rhinol 20 206-211.
108. RD Price, V Das-Gupta, IM Leigh and HA Navsaria (2006) A comparison of tissue-engineered hyaluronic acid dermal matrices in a human wound model. Tissue Eng 12 2985-2995.